Applied BioCode Corp.

As of June 30, 2026, Applied BioCode Corp. carries a market capitalization of 2.35B, placing it among publicly traded companies globally. Its enterprise value stands at 1.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Applied BioCode Corp.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Applied BioCode Corp. has 102.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.54, and the price-to-book ratio stands at 3.35.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.84B versus a market cap of 2.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Applied BioCode Corp. maintains a current ratio of 7.25, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.32, indicating elevated leverage, while an interest coverage ratio of -3.42 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Applied BioCode Corp. posted a negative return on equity (ROE) of -6.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.69, reflecting losses generated across the asset base. The company generates approximately 11.49M in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.34 indicates how many times Applied BioCode Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Applied BioCode Corp. recorded 236,000.00 in income tax expense. The company reported a pretax loss of -48.65M and -48.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Applied BioCode Corp.'s stock has gained approximately 30.89% over the past 52 weeks. The 50-day moving average sits at 28.02, while the 200-day moving average is 25.21.

Over the twelve months ended June 30, 2026, Applied BioCode Corp. generated 666.54M in revenue and converted that into -48.89M in net income, yielding earnings per share of -0.47. EBITDA reached -10.60M, while operating income came in at -63.11M.

As of June 30, 2026, Applied BioCode Corp. holds 557.34M in cash and equivalents against 51.32M in total debt, resulting in a net debt position of -449.17M. Total book value stands at 701.53M, with working capital of 805.22M providing operational flexibility.

Applied BioCode Corp. produced -84.74M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.64M in capital expenditures, free cash flow totaled -93.38M - equivalent to -0.90 per share.

Over the twelve months ended June 30, 2026, Applied BioCode Corp. posted a gross margin of 62.27, reflecting its pricing power and cost economics. The operating margin of -9.47 and net profit margin of -7.33 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.81, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Applied BioCode Corp. shareholders.

Applied BioCode Corp.'s most recent stock split took place on July 2, 2024 with a 997:1055 split ratio.

As of June 30, 2026, Applied BioCode Corp. has an Altman Z-Score of 4.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.